AOD-9604 in Haillot — Fat Loss Peptide Research Guide
AOD-9604 research guide for Haillot. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
The quest for AOD-9604 in Haillot almost always leads to the same conclusion: research peptides are distributed through specialist online vendors, not local retail. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. What consistently distinguishes top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. This guide gives Haillot researchers the methodology to verify sourcing options methodically and source high-purity AOD-9604 with confidence.
How AOD-9604 Works — Mechanisms & Research
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Haillot studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source AOD-9604 — Vendor Guide
The first step for any Haillot researcher sourcing AOD-9604 is locating suppliers that experienced researchers actively recommend — search results alone are too heavily influenced by marketing spend. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be 98% or higher. For Haillot researchers evaluating vendors with limited track records: a small initial order to verify quality before committing to research quantities is what experienced peptide researchers consistently do. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 30 days refrigerated.
Order AOD-9604 — ships to Haillot
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Lyophilised AOD-9604 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Verify the endotoxin level in your AOD-9604 batch COA before use in any in-vivo protocol — look for results reported in endotoxin units per mg or mL and compare against acceptable research limits for your application. Protocol documentation — recording exactly what was used, when, and how — is a sound practice for any AOD-9604 protocol that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
